Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer
- Author(s)
- Solomon, BJ; Liu, G; Felip, E; Mok, TSK; Soo, RA; Mazieres, J; Shaw, AT; Marinis, F; Goto, Y; Wu, YL; Kim, DW; Martini, JF; Messina, R; Paolini, J; Polli, A; Thomaidou, D; Toffalorio, F; Bauer, TM;
- Journal Title
- Future Oncology
- Publication Type
- Online publication before print
- Abstract
- WHAT IS THIS STUDY ABOUT? This is a summary of the results of an ongoing study called CROWN. In the CROWN study, researchers looked at the effects of two medicines called lorlatinib (Lorbrena) and crizotinib (Xalkori) for people with advanced non-small cell lung cancer (NSCLC) who had not been treated yet. Everyone in the study had changes in a gene called anaplastic lymphoma kinase, or ALK, in their cancer cells. The changes in the ALK gene can make cancer grow. This analysis looked at how well lorlatinib and crizotinib worked and their side effects in people with advanced ALK-positive NSCLC after 5 years. WHAT DID THIS STUDY FIND? After observing people for an average of 5 years, researchers found that more people who took lorlatinib were still alive without their cancer getting worse than the people who took crizotinib. At 5 years, the probability of being alive without their cancer getting worse was 60% in people who took lorlatinib compared with 8% in people who took crizotinib. Fewer people who took lorlatinib had their cancer spread within or to the brain than the people who took crizotinib. In more than half of the people who took lorlatinib, tumors that had spread to the brain did not get worse, and no new tumors spread to the brain after 5 years. In contrast, in about half of the people who took crizotinib, tumors that had spread to the brain got worse or new tumors spread to the brain after 16.4 months. More people who took lorlatinib (115 out of 149, or 77%) had severe or life-threatening side effects than people who took crizotinib (81 out of 142, or 57%). These side effects were like the ones reported in the earlier 3-year analysis. WHAT DO THE FINDINGS OF THE STUDY MEAN? The 5-year results from the CROWN study showed that more people who took lorlatinib continued to benefit from their treatment than those who took crizotinib. The 5-year benefit of lorlatinib in people with ALK-positive NSCLC has never been seen before.Clinical Trial Registration: NCT03052608 (Phase 3 CROWN study) (ClinicalTrials.gov).
- Keywords
- 5-year results; ALK inhibitor; Crown; clinical trial; crizotinib; lorlatinib; non-small cell lung cancer; plain language summary
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1080/14796694.2024.2406117
- Open Access at Publisher's Site
https://doi.org/10.1080/14796694.2024.2406117- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-11-07 06:46:49
Last Modified: 2024-11-07 06:54:52